bioRxiv Science⌕ Search

Biology subjects

Shady, M.

Publications and source records attributed to Shady, M..

3 recordsLinked to original sources

Evaluating agentic AI for biological discovery in autonomous and copilot settings

Advances in large language models (LLMs)-based artificial intelligence (AI) agents have improved their ability to execute structured analytical workflows, including standard bioinformatic pipelines for biological discovery. However, computational biology rarely consists of deterministic pipeline execution alone. Biological datasets are heterogeneous and noisy, and meaningful discovery often requires open-ended hypothesis generation and iterative reasoning over multimodal evidence. These challenges are particularly evident in multi-omic studies, where paired molecular modalities and heterogeneous clinical contexts create both opportunities and obstacles for discovery. The extent to which emerging agentic AI systems can support or automate this mode of scientific discovery remains poorly understood. Here, we systematically evaluated the capabilities and limitations of agentic AI for biological discovery using multi-omic single cell datasets spanning 11 cancer types. We developed the Multistep Multimodal Multiomic Agentic (M3A) Framework to support LLM-driven reasoning over persistent multimodal data states and to capture agentic reasoning behavior in autonomous and human-AI copilot settings. Using this framework, we assessed AI agents across complementary tasks, including autonomous cell-type annotation, generation of falsifiable biological hypotheses from gene programs, and copilot experiments testing the effect of human involvement and domain expertise. We found that current AI agents are effective at broad, systemic exploration of complex data, whereas domain experts remain critical for methodological guidance and biological synthesis across analyses. Together, our results delineate the current potential and boundaries of agentic AI in computational biology, and establish a framework for evaluating AI systems designed to support biological discovery.

cancer biology↗

Segregating DNA lesions point to high selective advantage of tumor initiating cells

The complications with identifying cells at the origin of cancer and tracking their early divisions impede studies of cancer initiation. Recently, it was shown that some DNA lesions generated by a pulse of damage-inducing mutagen persist over multiple rounds of replication. Segregation of DNA lesions in the early genealogy of an expanding clone leaves a statistically interpretable footprint of cancer initiating events. Specifically, it allows for estimating the number of cell divisions between the initiating DNA lesion and the most recent common ancestor of the tumor. Here, we analyze footprints of segregating lesions from a previously published experimental mouse system, as well as post-chemotherapy human metastatic tumors and the blood of chemotherapy treated patients. In all contexts, clones tend to start early, usually within the span of 4 cell generations from mutagen exposure. Using a branching process model, we show that fitness advantage of early cancer drivers exceeds 30%, with each early division leading to at least 1.3 self-renewing cells. We highlight an example of a blood-derived single cell phylogeny with major subclones separated by just two cell divisions. Broadly, our approach allows inference of tumor initiation and growth parameters based on events preceding the most recent common ancestor of the initiating clone as opposed to characteristics of fully grown tumors.

cancer biology↗

A rectal cancer model establishes a platform to study individual responses to chemoradiation

Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation, and surgery to optimize outcomes for individual patients. No accurate model of RC exists to answer fundamental research questions relevant to individual patients. We established a biorepository of 32 patient-derived RC organoid cultures (tumoroids) from patients with primary, metastatic, or recurrent disease. RC tumoroids retained molecular features of the tumors from which they were derived, and their ex vivo responses to clinically relevant chemotherapy and radiation treatment correlate well with responses noted in individual patients tumors. Upon engraftment into murine rectal mucosa, human RC tumoroids gave rise to invasive rectal cancer followed by metastasis to lung and liver. Importantly, engrafted tumors closely reflected the heterogenous sensitivity to chemotherapy observed clinically. Thus, the biology and drug sensitivity of RC clinical isolates can be efficiently interrogated using an organoid-based, in vitro platform coupled with endoluminal propagation in animals.

cancer biology↗